Related Experiment Video

Updated: Oct 10, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Left ventricular midwall function improves with antihypertensive therapy and regression of left ventricular

A E Schussheim1, J A Diamond, R A Phillips

  • 1Hypertension Section, The Zena and Michael A Wiener Cardiovascular Institute, The Mount Sinai Medical Center, New York, New York 10029, USA.

The American Journal of Cardiology
|January 4, 2001
PubMed

Insights

Antihypertensive therapy improves cardiac performance in patients with left ventricular hypertrophy (LVH). This therapy enhances midwall function, a key indicator of heart health, suggesting a role in managing hypertensive heart disease.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Echocardiography

Background:

  • Left ventricular hypertrophy (LVH) regression with antihypertensive therapy may improve prognosis.
  • The underlying mechanisms for this benefit are not fully understood.
  • Midwall fractional shortening (mFS) is a sensitive marker of myocardial performance, often reduced in hypertensive patients with LVH.

Purpose of the Study:

  • To investigate whether antihypertensive therapy can improve midwall function.
  • To assess changes in cardiac performance using mFS and conventional echocardiographic parameters.
  • To explore the relationship between antihypertensive therapy, LV mass regression, and cardiac function.

Main Methods:

  • Serial echocardiographic measurements of mFS and other chamber function parameters.
  • Study involved 29 hypertensive individuals over 6 months of drug therapy.
  • Analysis included stress-adjusted and absolute midwall function.

Main Results:

  • Significant improvements in both stress-adjusted (10%) and absolute (11%) midwall function were observed (p <0.05).
  • No significant changes were noted in other conventional measures of chamber function.
  • Improved function was more pronounced in patients with concentric remodeling and greater LV mass reduction.

Conclusions:

  • Antihypertensive therapy is associated with improved cardiac performance, as measured by mFS.
  • LV mass regression during antihypertensive treatment correlates with enhanced cardiac function.
  • mFS may be valuable for identifying early hypertensive heart disease and monitoring therapeutic responses.

More Related Videos

Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice08:21

Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice

Published on: June 15, 2020

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents07:26

Studying Left Ventricular Reverse Remodeling by Aortic Debanding in Rodents

Published on: July 14, 2021

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...